Relapse patterns and radiation dose exposure in IDH wild-type glioblastoma at first radiographic recurrence following chemoradiation.
Glioblastoma
Patterns of progression
Radiation therapy
Journal
Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
28
07
2022
accepted:
20
08
2022
pubmed:
3
9
2022
medline:
3
11
2022
entrez:
2
9
2022
Statut:
ppublish
Résumé
To quantify the radiation dose distribution and lesion morphometry (shape) at baseline, prior to chemoradiation, and at the time of radiographic recurrence in patients with glioblastoma (GBM). The IMRT dose distribution, location of the center of mass, sphericity, and solidity of the contrast enhancing tumor at baseline and the time of tumor recurrence was quantified in 48 IDH wild-type GBM who underwent postoperative IMRT (2 Gy daily for total of 60 Gy) with concomitant and adjuvant temozolomide. Average radiation dose within enhancing tumor at baseline and recurrence was ≥ 60 Gy. Centroid location of the enhancing tumor shifted an average of 11.3 mm at the time of recurrence with respect to pre-IMRT location. A positive correlation was observed between change in centroid location and PFS in MGMT methylated patients (P = 0.0007) and Cox multivariate regression confirmed centroid distance from baseline was associated with PFS when accounting for clinical factors (P = 0.0189). Lesion solidity was higher at recurrence compared to baseline (P = 0.0118). Tumors that progressed > 12 weeks after IMRT were significantly more spherical (P = 0.0094). Most GBMs recur local within therapeutic IMRT doses; however, tumors with longer PFS occurred further from the original tumor location and were more solid and/or nodular.
Identifiants
pubmed: 36053452
doi: 10.1007/s11060-022-04123-3
pii: 10.1007/s11060-022-04123-3
pmc: PMC9622513
doi:
Substances chimiques
Temozolomide
YF1K15M17Y
Antineoplastic Agents, Alkylating
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
115-125Subventions
Organisme : NCI NIH HHS
ID : P50 CA211015
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM008042
Pays : United States
Organisme : NCI NIH HHS
ID : NIH/NCI R21CA223757
Pays : United States
Organisme : NCI NIH HHS
ID : NIH/NCI P50CA211015
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
Neuro Oncol. 2015 Sep;17(9):1188-98
pubmed: 26250565
Cancer Cell. 2010 Jan 19;17(1):98-110
pubmed: 20129251
Surg Oncol. 2019 Jun;29:178-183
pubmed: 31196485
Int J Radiat Oncol Biol Phys. 2007 Nov 1;69(3):820-4
pubmed: 17499453
Radiology. 2014 Apr;271(1):200-10
pubmed: 24475840
J Clin Oncol. 2009 Mar 10;27(8):1275-9
pubmed: 19188675
Sci Rep. 2017 Feb 08;7:42148
pubmed: 28176884
Nature. 2018 Aug;560(7717):243-247
pubmed: 30069053
Bioinformatics. 2014 Jan 1;30(1):50-60
pubmed: 24177718
Lancet Oncol. 2008 May;9(5):453-61
pubmed: 18452856
J Cereb Blood Flow Metab. 2020 Mar;40(3):528-538
pubmed: 30732550
Radiat Oncol. 2018 Dec 19;13(1):251
pubmed: 30567592
Clin Cancer Res. 2018 Jun 1;24(11):2559-2573
pubmed: 29500275
Sci Rep. 2018 Mar 14;8(1):4561
pubmed: 29540809
Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):343-9
pubmed: 23462419
Cancer Cell. 2015 Sep 14;28(3):318-28
pubmed: 26373279
BMC Cancer. 2021 Jun 22;21(1):720
pubmed: 34154559
Onco Targets Ther. 2016 Mar 02;9:1115-22
pubmed: 27042103
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
Int J Radiat Oncol Biol Phys. 2013 Jul 15;86(4):616-22
pubmed: 23540348
Int J Radiat Oncol Biol Phys. 2011 Jan 1;79(1):130-6
pubmed: 20399036
Pract Radiat Oncol. 2016 Jul-Aug;6(4):217-225
pubmed: 27211230
Br J Radiol. 2016 Dec;89(1068):20160575
pubmed: 27781499
Oncogene. 2016 Nov 10;35(45):5819-5825
pubmed: 27041580
Neurotherapeutics. 2017 Apr;14(2):307-320
pubmed: 28108885
Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):877-85
pubmed: 25257812
JAMA. 2017 Dec 19;318(23):2306-2316
pubmed: 29260225
Radiat Oncol. 2021 Feb 18;16(1):36
pubmed: 33602305
J Clin Oncol. 2010 Apr 10;28(11):1963-72
pubmed: 20231676
Neuro Oncol. 2013 Jan;15(1):4-27
pubmed: 23136223
Sci Rep. 2019 Mar 13;9(1):4329
pubmed: 30867443
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S20-7
pubmed: 20171513
Int J Cancer. 2010 Nov 1;127(9):2106-18
pubmed: 20131314
J Neurooncol. 2017 Mar;132(1):55-62
pubmed: 28074320
Sci Rep. 2018 Mar 23;8(1):5087
pubmed: 29572492
J Neurooncol. 2020 May;147(3):643-652
pubmed: 32239430